CLAIMS

Claims 1-24 (canceled).

Claim 25 (currently amended): Cancer treatment method comprising:

implanting a bioresorbable delivery system into ~~a wound~~ **tissue containing one or more cancers selected from the group consisting of breast cancer, prostate cancer and colon cancer** for releasing first and second cytotoxic agents in a predetermined chronologic sequence with the first cytotoxic agent being released first followed by release of the second cytotoxic agent; and

radiating the wound during release of the second cytotoxic agent and after initial release of the first cytotoxic agent**, wherein said implanting and radiating effectively treats the one or more cancers**.

Claim 26 (original): The cancer treatment method of claim 25 with the first and second cytotoxic agents being each released initially at high local concentrations followed by a lower but sustained systemic release.

Claim 27 (currently amended): The cancer treatment method of claim 26 with the first cytotoxic agent adapted to paralyze a cell's cyctoskeleton and with the second cytotoxic agent adapted to damage a cell's ability to accurately ~~replate~~ **replicate**, with radiating ~~the wound~~ damaging a cell's ability to repair damaged DNA.

Claim 28 (original): The cancer treatment method of claim 26 with the first cytotoxic agent being paclitaxel and with the second cytotoxic agent being cisplatin.

Claim 29 (previously presented): The cancer treatment method of claim 25 wherein the bioresorbable delivery system comprises a first bioresorbable delivery vehicle which is hydrophobic, with the second cytotoxic agent different from but complimentary to the first cytotoxic agent, with the first cytotoxic agent being a cargo in the first bioresorbable vehicle for delivery of the first cytotoxic agent during resorption of the first bioresorbable delivery vehicle, with the first bioresorbable vehicle including void spaces; a second bioresorbable delivery vehicle which is hydrophilic, with the second cytotoxic agent being a cargo in the second bioresorbable vehicle for delivery of the second cytotoxic agent during resorption of the second bioresorbable delivery vehicle, with the second bioresorbable delivery vehicle and the second cytotoxic agent located in the void spaces of the first bioresorbable delivery vehicle.

Claim 30 (previously presented): The cancer treatment method of claim 29 further comprising chemically binding the second cytotoxic agent to the second bioresorbable delivery vehicle.

Claim 31 (previously presented): The cancer treatment method of claim 30 further comprising conjugating the second bioresorbable delivery vehicle to the second cytotoxic agent.

Claim 32 (previously presented): The cancer treatment method of claim 31 wherein the second bioresorbable delivery vehicle comprises hyaluronic acid.

Claim 33 (previously presented): The cancer treatment method of claim 32 with the hyaluronic acid having a high molecular weight.

Claim 34 (previously presented): The cancer treatment method of claim 31 with the second cytotoxic agent being paclitaxel.

Claim 35 (previously presented): The cancer treatment method of claim 34 with the first cytotoxic agent being cisplatin.

Claim 36 (previously presented): The cancer treatment method of claim 35 further comprising defining the void spaces of the first bioresorbable delivery vehicle by an internal architecture of partially enclosed, randomly sized, shaped and positioned intercommunicating interstices dictating a final three-dimensional morphology of repair tissue.

Claim 37 (previously presented): The cancer treatment method of claim 36 with the first bioresorbable delivery vehicle being formed of a bioresorbable material selected from a group of alphahydroxy acids.

Claim 38 (previously presented): The cancer treatment method of claim 31 further comprising blending high molecular weight hyaluronic acid with the conjugation.

Claim 39 (previously presented): The cancer treatment method of claim 29 with the first cytotoxic agent adapted to damage a cell's ability to accurately replicate, and with the second cytotoxic agent adapted to paralyze a cell's cytoskeleton.

Claim 40 (canceled).